Ebola Vaccine

This is a vaccine designed to protect people from getting sick with Ebola. It's like a shield your body builds to fight the Ebola virus. Doctors use it to help stop the spread of the disease.

Brand names:Ervebo
Medication

What people taking Ebola Vaccine report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Ebola Vaccine

What It's For

Ervebo is the only Ebola vaccine licensed by the US Food and Drug Administration (FDA). It is approved to prevent disease caused by Zaire ebolavirus, the Ebola species behind most recorded outbreaks, including the two largest in history, in people 12 months of age and older. During outbreaks it is used to vaccinate contacts of people who are sick, their contacts in turn, and frontline health workers. In the United States, Ebola vaccination is recommended for adults whose jobs put them at the highest risk of exposure: people responding to an outbreak, health care workers at the specialized hospitals that treat patients with suspected or confirmed Ebola, and staff at laboratories that handle the virus or patient specimens. It is not a routine vaccine for the general public or for ordinary travelers. Ervebo protects only against Zaire ebolavirus. It does not protect against other Ebola species, such as Sudan virus, or against the related Marburg virus, so it is not a solution for every outbreak.

How It Works

Ervebo is a live, weakened (attenuated) vaccine built from vesicular stomatitis virus (VSV), used here as a carrier. Scientists removed VSV's own surface protein and replaced it with the surface protein (glycoprotein) of Zaire ebolavirus. The resulting virus can multiply for a short time in the body, but it contains only that single Ebola protein, not the rest of the Ebola virus. As the vaccine virus copies itself, the immune system learns to recognize the Ebola glycoprotein, which the real virus uses to attach to and enter cells, and builds antibodies and other defenses against it. If the person is later exposed to Zaire ebolavirus, those defenses can respond quickly. Exactly which part of the immune response provides the protection is still not known.

Dosage & Administration

Ervebo is given as a single injection into a muscle, usually in the upper arm. No booster dose is currently part of the approved schedule. After the shot, the site is covered with a bandage until it stops leaking fluid, and the bandage is sealed in a plastic bag before being thrown away, because fluid from the site can contain vaccine virus. People are usually watched for about 15 minutes after vaccination so that a rare severe allergic reaction can be treated straight away. In the United States, Ervebo is not sold in pharmacies or clinics. The federal government stores it and supplies it at no cost, on request, to physicians who vaccinate people in the recommended groups.

Side Effects

Most people have some reaction, because the vaccine virus briefly multiplies in the body. Pain at the injection site, headache, fever or feeling feverish, muscle aches, tiredness, chills and joint pain are common, typically in the first days after the shot and usually mild to moderate. In young children fever is the most common reaction, affecting most toddlers in studies. Joint symptoms are worth knowing about. Joint pain usually starts within a day or two and settles within a week. Some people develop arthritis, meaning swollen, painful joints, which tends to start about a week after vaccination and usually clears within days to weeks, though some people have had symptoms that came back or lasted months. Women and people who have had arthritis before appear more likely to get it. A rash, sometimes with small fluid-filled blisters, can also appear. Report joint swelling or a rash to the clinician who gave the vaccine, and keep blisters covered with a bandage until they heal. Serious reactions are rare. In trials of nearly 19,000 people, two had anaphylaxis, a severe allergic reaction, and two had a serious fever.

Interactions & Warnings

Ervebo should not be given to anyone who has had a severe allergic reaction to any of its ingredients. Because the vaccine contains a protein made in rice, people with a severe rice allergy should not receive it. Because Ervebo is a live vaccine, its virus can be found in blood, saliva, urine and skin blisters for up to a few weeks, and passing it to others is possible in theory. Recommended precautions are not donating blood for at least 6 weeks; avoiding shared razors, needles, toothbrushes, cups or utensils, and open-mouth kissing, for 2 weeks (or until any mouth sores heal); using condoms or other barrier protection during sex for 2 months; and, for about 6 weeks, avoiding exposing people at higher risk (those with weak immune systems, pregnant or breastfeeding people and babies under 1 year) and livestock to your blood or body fluids. Pregnancy, breastfeeding and a weakened immune system call for an individual decision. There is not enough data to show whether the vaccine is safe in pregnancy, while Ebola infection itself is almost always fatal to a fetus. The vaccine may work less well in people with weakened immunity, and as a live vaccine it carries more uncertainty for them. The likelihood of exposure is weighed against these unknowns. Vaccination can make some Ebola blood tests turn positive, because those tests look for the same glycoprotein the vaccine produces. If a vaccinated person becomes ill after possible exposure, the care team needs to know about the vaccination so testing can look for other parts of the virus.

What to Expect

In the large outbreak study in Guinea, no one vaccinated right away developed confirmed Ebola from 10 days after vaccination onward, compared with 10 cases among people whose vaccination was delayed by three weeks. That result is very encouraging, but the study was relatively small, and how long protection lasts is still unknown. The vaccine may not protect everyone. For that reason, vaccinated workers continue to use the full set of infection-control practices, including personal protective equipment, exactly as before. Vaccination is an extra layer of protection, not a replacement. Any fever or illness after a possible exposure still needs to be reported to your occupational health team right away and assessed, whether or not you have been vaccinated. Most side effects pass within a few days, though joint symptoms can take longer. The transmission precautions above continue for the weeks that follow.

Questions to Ask Your Doctor

  1. 1.Does my job or planned deployment put me in a group for which Ebola vaccination is recommended?
  2. 2.Does the outbreak I may face involve Zaire ebolavirus, or a species this vaccine does not cover?
  3. 3.Given my history of arthritis, allergies, pregnancy plans or immune conditions, what are my particular risks from the vaccine?
  4. 4.Which precautions should I follow at home and at work in the weeks after vaccination, and for how long?
  5. 5.How should I report a fever or possible exposure after vaccination, and how will testing account for the vaccine?

Last reviewed • Oct 2026

Educational content, not medical advice.